A real-world multicenter study of dostarlimab in patients with recurrent or advanced DNA mismatch repair deficient/microsatellite instability-high (MMRd/MSI-H) endometrial cancer. Translational study title: Comparison of the Promega® and Idylla® PCR-based techniques, immunohistochemistry and MMR genetic and epigenetic alterations as predictive biomarkers for dostarlimab.